Pharmala Biotech Holdings Inc
Pharmala Biotech Holdings Inc., a biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredients under the LaNeo brand. The company is headquartered in Vancouver, Canada.
Pharmala Biotech Holdings Inc (MDXXF) - Net Assets
Latest net assets as of November 2025: $2.37 Million USD
Based on the latest financial reports, Pharmala Biotech Holdings Inc (MDXXF) has net assets worth $2.37 Million USD as of November 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.40 Million) and total liabilities ($1.03 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.37 Million |
| % of Total Assets | 69.77% |
| Annual Growth Rate | -1.91% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 31.47 |
Pharmala Biotech Holdings Inc - Net Assets Trend (2021–2025)
This chart illustrates how Pharmala Biotech Holdings Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Pharmala Biotech Holdings Inc (2021–2025)
The table below shows the annual net assets of Pharmala Biotech Holdings Inc from 2021 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-08-31 | $2.46 Million | +24.06% |
| 2024-08-31 | $1.98 Million | +43.21% |
| 2023-08-31 | $1.38 Million | -27.42% |
| 2022-08-31 | $1.91 Million | -28.21% |
| 2021-08-31 | $2.66 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pharmala Biotech Holdings Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 462212300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (August 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $9.59 Million | 390.10% |
| Total Equity | $2.46 Million | 100.00% |
Pharmala Biotech Holdings Inc Competitors by Market Cap
The table below lists competitors of Pharmala Biotech Holdings Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Aurea SA
PA:AURE
|
$8.89 Million |
|
Daewoo SBI SPAC 1
KQ:215480
|
$8.89 Million |
|
Gaxos.ai Inc
NASDAQ:GXAI
|
$8.89 Million |
|
Wow Factor PCL
BK:W
|
$8.89 Million |
|
Sparc Technologies Ltd
AU:SPN
|
$8.88 Million |
|
Advancecon Holdings Bhd
KLSE:5281
|
$8.88 Million |
|
Mendus AB (publ)
ST:IMMU
|
$8.88 Million |
|
YD More Investments Ltd
TA:MRIN
|
$8.88 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pharmala Biotech Holdings Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,981,360 to 2,458,150, a change of 476,790 (24.1%).
- Net loss of 2,175,244 reduced equity.
- New share issuances of 1,527,572 increased equity.
- Other factors increased equity by 1,124,462.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.18 Million | -88.49% |
| Share Issuances | $1.53 Million | +62.14% |
| Other Changes | $1.12 Million | +45.74% |
| Total Change | $- | 24.06% |
Book Value vs Market Value Analysis
This analysis compares Pharmala Biotech Holdings Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.08x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 3.66x to 5.08x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-08-31 | $0.03 | $0.12 | x |
| 2022-08-31 | $0.02 | $0.12 | x |
| 2023-08-31 | $0.02 | $0.12 | x |
| 2024-08-31 | $0.02 | $0.12 | x |
| 2025-08-31 | $0.02 | $0.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pharmala Biotech Holdings Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -88.49%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -359.25%
- • Asset Turnover: 0.18x
- • Equity Multiplier: 1.39x
- Recent ROE (-88.49%) is below the historical average (-66.52%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -94.49% | 0.00% | 0.00x | 1.05x | $-2.77 Million |
| 2022 | -51.70% | -1262.43% | 0.03x | 1.22x | $-1.18 Million |
| 2023 | -56.36% | -146.58% | 0.22x | 1.74x | $-918.16K |
| 2024 | -41.57% | -79.55% | 0.36x | 1.46x | $-1.02 Million |
| 2025 | -88.49% | -359.25% | 0.18x | 1.39x | $-2.42 Million |
Industry Comparison
This section compares Pharmala Biotech Holdings Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pharmala Biotech Holdings Inc (MDXXF) | $2.37 Million | -94.49% | 0.43x | $8.89 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |